PR Newswire
NEW YORK, Oct. 28, 2020
NEW YORK
,
Oct. 28, 2020
/PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between
February 11, 2020
and
August 10, 2020
, inclusive (the “Class Period”), of the important
November 2, 2020
lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Fennec investors under the federal securities laws.
To join the Fennec class action, go to
http://www.rosenlegal.com/cases-register-1926.html
or call
Phillip Kim, Esq.
toll-free at 866-767-3653 or email
[email protected]
or
[email protected]
for information on the class action.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose to investors that: (1) the manufacturing facilities for PEDMARK, Fennec’s sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) as a result of the foregoing, defendants’ positive statements about Fennec’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court
no later than
November 2, 2020
. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to
http://www.rosenlegal.com/cases-register-1926.html
or to discuss your rights or interests regarding this class action, please contact
Phillip Kim, Esq.
of Rosen Law Firm toll free at 866-767-3653 or via e-mail at
[email protected]
or
[email protected]
.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.
Follow us for updates on LinkedIn:
https://www.linkedin.com/company/the-rosen-law-firm
, on Twitter:
Tweets by rosen_firm
or on Facebook:
https://www.facebook.com/rosenlawfirm/
.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY
10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com
View original content to download multimedia:
http://www.prnewswire.com/news-releases/final-deadline-notice-rosen-global-investor-counsel-reminds-fennec-pharmaceuticals-inc-investors-of-the-important-november-2-deadline-in-securities-class-action–fenc-301162336.html
SOURCE Rosen Law Firm, P.A.
